JP2013505968A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013505968A5 JP2013505968A5 JP2012531186A JP2012531186A JP2013505968A5 JP 2013505968 A5 JP2013505968 A5 JP 2013505968A5 JP 2012531186 A JP2012531186 A JP 2012531186A JP 2012531186 A JP2012531186 A JP 2012531186A JP 2013505968 A5 JP2013505968 A5 JP 2013505968A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- leukemia
- receptor
- csf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010002386 Interleukin-3 Proteins 0.000 claims 6
- 102000000646 Interleukin-3 Human genes 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 102000005962 receptors Human genes 0.000 claims 6
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 5
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 4
- 208000032839 leukemia Diseases 0.000 claims 4
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 4
- -1 restaurtinib Chemical compound 0.000 claims 3
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 3
- 206010000830 Acute leukaemia Diseases 0.000 claims 2
- 229940124290 BCR-ABL tyrosine kinase inhibitor Drugs 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 108010001857 Cell Surface Receptors Proteins 0.000 claims 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 2
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims 2
- 239000005536 L01XE08 - Nilotinib Substances 0.000 claims 2
- 239000002118 L01XE12 - Vandetanib Substances 0.000 claims 2
- 208000036676 acute undifferentiated leukemia Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 229960002448 dasatinib Drugs 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 102000006240 membrane receptors Human genes 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229960001346 nilotinib Drugs 0.000 claims 2
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims 2
- 229960000241 vandetanib Drugs 0.000 claims 2
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims 2
- INAGORZAOFUKOZ-UHFFFAOYSA-N 2-amino-5-[3-(1-ethyl-1h-pyrazol-5-yl)-1h-pyrrolo[2,3-b]pyridin-5-yl]-n,n-dimethylbenzamide Chemical compound CCN1N=CC=C1C1=CNC2=NC=C(C=3C=C(C(N)=CC=3)C(=O)N(C)C)C=C12 INAGORZAOFUKOZ-UHFFFAOYSA-N 0.000 claims 1
- IPDMWUNUULAXLU-UHFFFAOYSA-N 3-hydroxy-1-methoxy-9,10-dioxo-2-anthracenecarboxaldehyde Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C=C(O)C(C=O)=C2OC IPDMWUNUULAXLU-UHFFFAOYSA-N 0.000 claims 1
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims 1
- 150000004922 Dasatinib derivatives Chemical group 0.000 claims 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- 239000002145 L01XE14 - Bosutinib Substances 0.000 claims 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- XKFTZKGMDDZMJI-HSZRJFAPSA-N N-[5-[(2R)-2-methoxy-1-oxo-2-phenylethyl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl]-4-(4-methyl-1-piperazinyl)benzamide Chemical compound O=C([C@H](OC)C=1C=CC=CC=1)N(CC=12)CC=1NN=C2NC(=O)C(C=C1)=CC=C1N1CCN(C)CC1 XKFTZKGMDDZMJI-HSZRJFAPSA-N 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 1
- 229960003005 axitinib Drugs 0.000 claims 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims 1
- 229960003736 bosutinib Drugs 0.000 claims 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 claims 1
- 229960002412 cediranib Drugs 0.000 claims 1
- 229960005061 crizotinib Drugs 0.000 claims 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 229960002584 gefitinib Drugs 0.000 claims 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
- 229960002411 imatinib Drugs 0.000 claims 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 1
- 108040006856 interleukin-3 receptor activity proteins Proteins 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- 229950008835 neratinib Drugs 0.000 claims 1
- ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 229960001796 sunitinib Drugs 0.000 claims 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24766909P | 2009-10-01 | 2009-10-01 | |
| US61/247,669 | 2009-10-01 | ||
| PCT/AU2010/001295 WO2011038467A1 (en) | 2009-10-01 | 2010-10-01 | Method of treatment of philadelphia chromosome positive leukaemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013505968A JP2013505968A (ja) | 2013-02-21 |
| JP2013505968A5 true JP2013505968A5 (enExample) | 2013-07-18 |
Family
ID=43825444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012531186A Pending JP2013505968A (ja) | 2009-10-01 | 2010-10-01 | フィラデルフィア染色体陽性白血病の治療方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (7) | US20120244116A1 (enExample) |
| EP (1) | EP2470212A4 (enExample) |
| JP (1) | JP2013505968A (enExample) |
| CN (1) | CN102665756A (enExample) |
| AU (1) | AU2010302961A1 (enExample) |
| CA (1) | CA2775155A1 (enExample) |
| IL (1) | IL218774A0 (enExample) |
| WO (1) | WO2011038467A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108421044A (zh) | 2005-02-03 | 2018-08-21 | 综合医院公司 | 治疗吉非替尼耐药性癌症的方法 |
| BRPI0618042A2 (pt) | 2005-11-04 | 2011-08-16 | Wyeth Corp | usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| CN102641270A (zh) | 2008-06-17 | 2012-08-22 | 惠氏有限责任公司 | 含有hki-272和长春瑞滨的抗肿瘤组合 |
| US8669273B2 (en) | 2008-08-04 | 2014-03-11 | Wyeth Llc | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
| IL264349B2 (en) | 2009-04-06 | 2024-01-01 | Wyeth Llc | Regimen comprising neratinib for the treatment of cancer |
| JP5694923B2 (ja) | 2009-04-27 | 2015-04-01 | 協和発酵キリン株式会社 | 血液腫瘍治療を目的とした抗ＩＬ−３Ｒα抗体 |
| ES2624427T3 (es) * | 2011-11-06 | 2017-07-14 | Beta Cat Pharmaceuticals Llc | Tratamiento de enfermedades y trastornos relacionados con la actividad de proteína 1 de tipo transducina beta (TBL 1), incluyendo neoplasia mieloproliferativa y leucemia mieloide crónica |
| CA2855211A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | N-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide for the treatment of chronic myelogenous leukemia |
| US9801851B2 (en) * | 2012-05-23 | 2017-10-31 | St. Jude Children's Research Hospital | Methods and compositions for the treatment of BCR-ABL positive lymphoblastic leukemias |
| US9220706B2 (en) | 2012-06-01 | 2015-12-29 | National Institutes Of Health (Nih) | Inhibition of leukemic stem cells by PP2A activating agents |
| US9573988B2 (en) | 2013-02-20 | 2017-02-21 | Novartis Ag | Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells |
| JP6612232B2 (ja) | 2013-08-28 | 2019-11-27 | クラウン バイオサイエンス インコーポレイテッド（タイカン） | 対象のマルチキナーゼ阻害剤に対する応答性を予測する遺伝子発現シグネチャ、及びその使用 |
| CN106170297A (zh) * | 2013-09-20 | 2016-11-30 | 纪念斯隆-凯特琳癌症中心 | 用于wt‑1‑阳性疾病的组合/辅助疗法 |
| MY181834A (en) | 2014-07-21 | 2021-01-08 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
| JP6736540B2 (ja) | 2014-07-21 | 2020-08-05 | ノバルティス アーゲー | Ｃｌｌ−１キメラ抗原受容体を使用した癌の処置 |
| SG11201700770PA (en) | 2014-08-19 | 2017-03-30 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
| WO2017042944A1 (ja) * | 2015-09-10 | 2017-03-16 | 国立大学法人山梨大学 | フィラデルフィア染色体陽性（Ｐｈ＋）急性リンパ性白血病（ＡＬＬ）の治療薬又は治療方法 |
| JP6931889B2 (ja) * | 2016-01-13 | 2021-09-08 | 学校法人早稲田大学 | 白血病幹細胞のニッチ形成抑制活性を有する海洋生物由来の抽出物、化合物及び医薬組成物 |
| CN108473487B (zh) | 2016-12-13 | 2021-08-03 | 普林斯顿药物研发公司 | 一种蛋白激酶抑制剂 |
| AU2019284911B2 (en) | 2018-06-13 | 2026-04-09 | Novartis Ag | BCMA chimeric antigen receptors and uses thereof |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
| CN120919138A (zh) * | 2025-08-19 | 2025-11-11 | 深圳大学 | 一种用于治疗白血病的药物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5070013A (en) * | 1988-05-31 | 1991-12-03 | Schering Corporation | Immunochemical assay for human granulocyte-macrophage colony stimulating factor |
| WO1991002063A1 (en) * | 1989-08-11 | 1991-02-21 | Amrad Corporation Limited | Improvements in granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof |
| US5281699A (en) * | 1990-06-01 | 1994-01-25 | Tanox Biosystems, Inc. | Treating B cell lymphoma or leukemia by targeting specific epitopes on B cell bound immunoglobulins |
| US5112961A (en) * | 1990-07-18 | 1992-05-12 | Schering Corporation | Dna encoding subunits of a high affinity gm-csf receptor |
| EP2329847B1 (en) * | 2000-03-06 | 2016-11-02 | University of Kentucky Research Foundation | Use of an antibody or an immunotoxin that selectively binds to cd123 to impair hematologic cancer progenitor cells |
| US20060235006A1 (en) * | 2005-04-13 | 2006-10-19 | Lee Francis Y | Combinations, methods and compositions for treating cancer |
| WO2008052277A1 (en) * | 2006-11-03 | 2008-05-08 | St. Vincent's Institute Of Medical Research | Crystalline composition of gm-csf/gm-csfr |
| WO2008127735A1 (en) * | 2007-04-13 | 2008-10-23 | Stemline Therapeutics, Inc. | Il3ralpha antibody conjugates and uses thereof |
| EP2231187A4 (en) * | 2007-12-06 | 2013-02-20 | Csl Ltd | PROCESS FOR SUPPRESSING LEUKEMIA STEM CELLS |
| JP5694923B2 (ja) * | 2009-04-27 | 2015-04-01 | 協和発酵キリン株式会社 | 血液腫瘍治療を目的とした抗ＩＬ−３Ｒα抗体 |
-
2010
- 2010-10-01 JP JP2012531186A patent/JP2013505968A/ja active Pending
- 2010-10-01 EP EP10819752.6A patent/EP2470212A4/en not_active Withdrawn
- 2010-10-01 US US13/499,436 patent/US20120244116A1/en not_active Abandoned
- 2010-10-01 WO PCT/AU2010/001295 patent/WO2011038467A1/en not_active Ceased
- 2010-10-01 AU AU2010302961A patent/AU2010302961A1/en not_active Abandoned
- 2010-10-01 CA CA2775155A patent/CA2775155A1/en not_active Abandoned
- 2010-10-01 CN CN2010800447477A patent/CN102665756A/zh active Pending
-
2012
- 2012-03-22 IL IL218774A patent/IL218774A0/en unknown
-
2014
- 2014-10-17 US US14/517,254 patent/US20150093355A1/en not_active Abandoned
-
2016
- 2016-06-27 US US15/193,784 patent/US20160304616A1/en not_active Abandoned
-
2017
- 2017-08-30 US US15/690,826 patent/US20170362328A1/en not_active Abandoned
-
2019
- 2019-09-24 US US16/580,012 patent/US20200277389A1/en not_active Abandoned
-
2021
- 2021-03-18 US US17/205,585 patent/US20210292424A1/en not_active Abandoned
-
2024
- 2024-07-17 US US18/775,212 patent/US20250122295A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2775155A1 (en) | Method of treatment of philadelphia chromosome positive leukemia | |
| TW202327569A (zh) | 包含ｔｅａｄ抑制劑的藥物組合及其用於癌症治療之用途 | |
| Goździk-Spychalska et al. | C-MET inhibitors in the treatment of lung cancer | |
| FI3569620T3 (fi) | Ihmisen cgrp-reseptoria sitovat vasta-aineet | |
| WO2018237158A1 (en) | Methods for treating cancer | |
| JP2010515709A5 (enExample) | ||
| CN107106685A (zh) | 协同澳瑞他汀组合 | |
| RU2010118448A (ru) | Комбинированная терапия антителами анти-cd20 типа ii в сочетании с активным агентом анти-bcl-2 | |
| MX2014002471A (es) | Combinaciones sinergicas de los inhibidores de p13k y mek. | |
| UA116871C2 (uk) | СПОСІБ ЛІКУВАННЯ МІЄЛОДИСПЛАСТИЧНОГО СИНДРОМУ, ТАЛАСЕМІЇ ТА СЕРПОПОДІБНО-КЛІТИННОЇ АНЕМІЇ ЗА ДОПОМОГОЮ ЗАСТОСУВАННЯ АНТАГОНІСТА АКТИВІНУ ПОЛІПЕПТИДУ ActRII | |
| EP2526934A3 (en) | Inhibitors of bruton's tyrosine kinase | |
| IL301603A (en) | Pertuzumab, trastuzumab, docetaxel and carboplatin for use in the preoperative treatment of a patient | |
| JP2020505433A5 (enExample) | ||
| JP2009518447A5 (enExample) | ||
| JP2007527914A5 (enExample) | ||
| JP2014525454A5 (enExample) | ||
| JP2008508279A5 (enExample) | ||
| ES2844629T3 (es) | Tratamiento de la infección por el virus de la hepatitis delta | |
| KR20190130644A (ko) | 항암 조합 요법 | |
| US12290509B2 (en) | Treatment of hepatitis delta virus infection | |
| CN107249639A (zh) | 联用药物 | |
| WO2012154587A2 (en) | Methods for preventing toxic drug-drug interactions in combination therapies comprising anti-erbb3 agents | |
| RU2019124477A (ru) | Терапия мелкоклеточного рака легких (мкрл) с помощью конъюгата антитело-лекарственный препарат (кап), ингибирующего топоизомеразу-i, нацеленного на trop-2 | |
| Martin et al. | Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours | |
| UA94213C2 (ru) | Применение полипептида одноцепочечного антитела, который подавляет активность cd40 или cd40l в приготовлении медикамента для лечения аутоиммунного заболевания |